Relationship Between Baseline Low-Density Lipoprotein Cholesterol and Percent Low-Density Lipoprotein Cholesterol Reduction With Evolocumab in the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) Trial

被引：0
|
作者：
Marcusa, Dan P.
Giugliano, Robert P.
Park, Jeong-Gun
Sever, Peter
Wang, Huei
Hamer, Andrew
Pedersen, Terje R.
Keech, Anthony C.
Sabatine, Marc S.
机构：
来源：
CIRCULATION | 2020年 / 142卷
关键词：
D O I：
10.1161/circ.142.suppl_3.13200
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A13200
引用
收藏
页数：3
相关论文
共 50 条
  • [21] LOW-DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION IN PATIENTS AT VERY HIGH CARDIOVASCULAR RISK
    Cherubini, A.
    Tollardo, M.
    Palcic, S.
    Scagnetto, A.
    Russo, G.
    Capelletto, C.
    Bollini, M.
    Di Lenarda, A.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2023, 25
  • [22] Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
    Henry, Courtney A.
    Lyon, Ronald A.
    Ling, Hua
    VASCULAR HEALTH AND RISK MANAGEMENT, 2016, 12 : 163 - 169
  • [23] Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab An Analysis of FOURIER Trial Data
    Qamar, Arman
    Giugliano, Robert P.
    Keech, Anthony C.
    Kuder, Julia F.
    Murphy, Sabina A.
    Kurtz, Christopher E.
    Wasserman, Scott M.
    Sever, Peter S.
    Pedersen, Terje R.
    Sabatine, Marc S.
    JAMA CARDIOLOGY, 2019, 4 (01) : 59 - 63
  • [24] Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment
    Lahoz, C
    Peña, R
    Mostaza, JM
    Laguna, F
    García-Iglesias, MF
    Taboada, M
    Pintó, X
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2005, 54 (06): : 741 - 747
  • [25] Discordance Between Very Low-Density Lipoprotein Cholesterol and Low-Density Lipoprotein Cholesterol Increases Cardiovascular Disease Risk in a Geographically Defined Cohort
    Seehusen, Kristina E.
    Remaley, Alan T.
    Sampson, Maureen
    Meeusen, Jeffrey W.
    Larson, Nicholas B.
    Decker, Paul A.
    Killian, Jill M.
    Takahashi, Paul Y.
    Roger, Veronique L.
    Manemann, Sheila M.
    Lam, Reyna
    Bielinski, Suzette J.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (08):
  • [26] Low-Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events
    Willeit, Peter
    Yeang, Calvin
    Moriarty, Patrick M.
    Tschiderer, Lena
    Varvel, Stephen A.
    McConnell, Joseph P.
    Tsimikas, Sotirios
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (23):
  • [27] Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?
    Farnier, Michel
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (03)
  • [28] Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol
    Della Badia, Laura A.
    Elshourbagy, Nabil A.
    Mousa, Shaker A.
    PHARMACOLOGY & THERAPEUTICS, 2016, 164 : 183 - 194
  • [29] PCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicity
    Guijarro, Carlos
    JAMA CARDIOLOGY, 2017, 2 (10) : 1168 - +
  • [30] Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein-Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab
    Honda, Satoshi
    Puri, Rishi
    Anderson, Todd
    Kastelein, John J. P.
    Brennan, Danielle M.
    Kassahun, Helina
    Somaratne, Ransi
    Wasserman, Scott M.
    Nissen, Steve E.
    Nicholls, Stephen J.
    JACC-CARDIOVASCULAR IMAGING, 2022, 15 (04) : 709 - 711
12345